Intraperitoneal chemotherapy as primary treatment of advanced ovarian cancer: Efficacy, toxicity, and future directions

Reviews on Recent Clinical Trials

Volumn 2, Issue 3, 2007, Pages 169-173

  Markman, Maurie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; PACLITAXEL;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADVANCED CANCER; AREA UNDER THE CURVE; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OPTIMAL DRUG DOSE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; THROMBOCYTOPENIA; TINNITUS; TUMOR VOLUME; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; FORECASTING; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 35048842714     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488707781662698     Document Type: Review

References (45)

1. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
2. Trimble EL, Alvarez RD. Intraperitoneal chemotherapy and the NCI clinical announcement. Gynecol Oncol 2006; 103: S18-9.
3. Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review with a focus on practical aspects of treatment. J Clin Oncol 2006; 24: 988-94.
4. Ozols RF, Bookman MA, duBois A, et al. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol 2006; 103: 1-6.
5. Gore M, duBois A, Vergote I. Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol 2006; 24: 4528-530.
6. Armstrong DK, Brady MF. Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time. J Clin Oncol 2006; 24: 4531-3.
7. Cannistra SA. Intraperitoneal chemotherapy comes of age. N Engl J Med 2006; 354: 77-9.
8. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978; 62: 1-9.
9. Bergman F. Carcinoma of the ovary: A clinicopathological study of 86 autopsied cases with special reference to mode of spread. Acta Obstet Gynecol Scand 1966; 45: 211-31.
10. Dauplat J, Hacker NF, Nieberg RK, et al. Distant metastases in epithelial ovarian carcinoma. Cancer 1987; 60: 1561-6.
11. Markman M. Intraperitoneal drug delivery of antineoplastics. Drugs 2001; 61: 1057-65.
12. Alberts DS, Young L, Mason N, Salmon SE. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 1985;12: 38-42.
13. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 2003; 4: 277-83.
14. Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982; 97: 945-51.
15. Casper ES, Kelsen DP, Alcock NW, Lewis JL, Jr. Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep 1983; 67: 235-8.
16. Degregorio MW, Lum BL, Holleran WM, et al. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol 1986; 18: 235-8.
17. Elferink F, van der Vijgh WJ, Klein I, et al. Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol 1988; 21: 57-60.
18. Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol 1992; 10: 1485-91.
19. Francis P, Rowinsky E, Schneider J, et al. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group Pilot Study. J Clin Oncol 1995; 13: 2961-7.
20. Markman M, George M, Hakes T, et al. Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. J Clin Oncol 1990; 8: 146-50.
21. Ozols RF, Young RC, Speyer JL, et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 1982; 42: 4265-9.
22. Ozols RF, Locker GY, Doroshow JH, et al. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 1979; 39:3209-3214.
23. Los G, Mutsaers PHA, van der Vijgh WJF, et al. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy. Cancer Res 1989; 49:3380-4.
24. Nederman T, Carlsson J. Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother Pharmacol 1984; 13:131-5.
25. Markman M, Brady MF, Spirtos NM, et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study, J Clin Oncol 1998; 16: 2620-4.
26. Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991; 9: 1901-5.
27. Markman M, Reichman B, Hakes T, et al. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol 1992; 10: 1479-84.
28. Howell SB, Zimm S, Markman M, et al. Longterm survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987; 5: 1607-12.
29. Barakat RR, Sabbatini P, Bhaskaran D, et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol 2002; 20: 694-8.
30. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335:1950-5.
31. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 1001-7.
32. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with pactitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
33. Shapiro F, Schneider J, Markman M, et al. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with tenyear follow-up. Gynecol Oncol 1997; 67: 39-45.
34. McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995; 13:1589-99.
35. Gore M, Mainwaring P, A'Hern R, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients mdth epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 1998; 16: 2426-34.
36. Conte PF, Bruzzone M, Carnino F, et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 1996; 14: 351-6.
37. Jakobsen A, Bertelsen K, Andersen JE, et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 1997; 15: 193-8.
38. Covens A, Carey M, Bryson P, et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002; 85: 71-80.
39. Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992; 10: 706-17.
40. Swenerton K, Jeffrey J, Stuart G, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992; 10: 718-26.
41. duBois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-9.
42. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-200.
43. Davidson SA, Rubin SC, Markman M et al. Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol Oncol 1991; 41: 101-6.
44. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 2006; 100: 27-32.
45. Fujiwara K, Markman M, Morgan M, Cöleman RL. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol 2005; 97: 10-5.